EP2084182B1 - Composés antidiabétiques - Google Patents

Composés antidiabétiques Download PDF

Info

Publication number
EP2084182B1
EP2084182B1 EP07866718.5A EP07866718A EP2084182B1 EP 2084182 B1 EP2084182 B1 EP 2084182B1 EP 07866718 A EP07866718 A EP 07866718A EP 2084182 B1 EP2084182 B1 EP 2084182B1
Authority
EP
European Patent Office
Prior art keywords
bip
ome
phe
tsd
acp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP07866718.5A
Other languages
German (de)
English (en)
Other versions
EP2084182A2 (fr
Inventor
Rajesh H. Bahekar
Braj Bhushan Lohray
Vidya Bhushan Lohray
Mukul R. Jain
Kaushik M. Banerjee
Pankaj Ramanbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of EP2084182A2 publication Critical patent/EP2084182A2/fr
Application granted granted Critical
Publication of EP2084182B1 publication Critical patent/EP2084182B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

  • the present invention relates to novel compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts and pharmaceutical compositions containing them: A-Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 -Z 7 -Z 8 -Z 9 -Z 10 -Z 11 -B (I)
  • the present invention also relates to a process for preparing compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts and pharmaceutical compositions containing them.
  • Diabetes is characterized by impaired insulin secretion from pancreatic ⁇ -cells, insulin resistance or both ( Cavaghan, M.K., et al., J. Clin. Invest. 2000, 106, 329 ).
  • Majority of type 2 diabetic patients can be treated with agents that reduces hepatic glucose production (glucagon antagonist), reduce glucose absorption form GIT, stimulate ⁇ -cell function (insulin secretagogues) or with agents that enhance the tissue sensitivity of the patients towards insulin (insulin sensitizes).
  • the drugs presently used to treat type 2 diabetes include ⁇ -glucosidase inhibitors, insulin sensitizers, insulin secretagogues and K ATP channel blocker ( Chehade, J.
  • Insulin treatment has several drawbacks, it is injectable, produces hypoglycemia and causes weight gain ( Burge, M.R., Diabetes Obes. Metab., 1999, 1, 199 ).
  • glucagon-like peptide-1 (GLP-1) agonist which promote glucose-dependent insulin secretion in the pancreas and glucagon receptor antagonist, which inhibit hepatic glucose production by inhibiting glycogenolysis and gluconeogenesis, were found to be therapeutically potential.
  • GLP-1 agonist and glucagon antagonist together were found to reduce the circulating glucose levels and represent useful therapeutic agents for the treatment and prevention of type 2 diabetes ( Perry, T.A., et al., Trends Pharmacol. Sci., 2003, 24, 377 ).
  • Glucagon and GLP-1 are members of structurally related peptide hormone family (secretin family).
  • Glucagon and GLP-1 constitute a highly homologous set of peptides because these two hormones originate from a common precursor, preproglucagon, which upon tissue-specific processing leads to production of GLP-1 predominantly in the intestine and glucagon in the pancreas ( Jiang, G., et al., Am. J. Physiol. Endocrinol. Metab., 2003, 284, E671-678 ).
  • the receptors for these two peptides are homologous (58 % identity) and belong to the class B family of G-protein coupled receptors (GPCRs). Class-B GPCRS is also called as the secretin receptor family, which consist of 15 peptide-binding receptors in humans.
  • GPCR receptors comprise an extracellular N-terminal domain of 100-160 residues, connected to a juxtamembrane domain (J-domain) of seven membrane-spanning ⁇ -helices with intervening loops and a. C-terminal tail ( Bnibaker, P. L., et al., Receptors Channels, 2002, 8, 179 ).
  • Class B GPCRs are activated by endogenous peptide ligands of intermediate size, typically 30-40 amino acids ( Hoare, S.R.J., Drug. Discovery Today, 2005, 10, 423 ; Gether, U., Endocrine Reviews, 2000, 21, 90 ).
  • Glucagon is a 29-amino acid peptide hormone processed from proglucagon in pancreatic ⁇ -cells by PC2. Glucagon acts via a seven transmembrane GPCRs, consisting of 485 amino acids. Glucagon is released into the bloodstream when circulating glucose is low. The main physiological role of glucagon is to stimulate hepatic glucose output, thereby leading to increase in glycemia ( Tan, K., et al., Diabetologia, 1985, 28, 435 ). Glucagon provides the major counterregulatory mechanism for insulin in maintaining glucose homeostasis in vivo . Glucagon and its receptor represent potential targets for the treatment of diabetes.
  • glucagon antagonist glucagon antagonist
  • glucagon production itself represents a new avenue for intervention of diabetes and metabolic disorders ( Unson, C.G., et al., Peptides, 1989, 10, 1171 ; Parker, J. C., Diabetes, 2000, 49, 2079 ; Johnson, D. G., Science, 1982, 215, 1115 ).
  • the GLP-1 (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food.
  • the physiological action of GLP-1 has gained considerable interest.
  • GLP-1 exerts multiple action by stimulating insulin secretion from pancreatic ⁇ -cells, in a glucose dependent manner (insulinotropic action).
  • GLP-1 lowers circulating plasma glucagon concentration, by inhibiting its secretion (production) from ⁇ -cells ( Drucker D. J., Endocrinology 2001, 142, 521-527 ).
  • GLP-1 also exhibits properties like stimulation of ⁇ -cell growth, appetite suppression, delayed gastric emptying and stimulation of insulin sensitivity ( Nauck, M.A., Horm. Metab.
  • GLP-1 and EX-4 are in different stages of clinical development ( Nauck M.A., Regulatory Peptides, 2004, 115, 13 ).
  • the effector system of glucagon and GLP-1 receptors is the Adenylyl Cyclase (AC) enzyme.
  • AC Adenylyl Cyclase
  • GLP-1 R glucagon or GLP-1 receptors
  • AC Adenylyl Cyclase
  • Increase in the intracellular cAMP level raises the ratio of ADP/ATP, thereby initiating the cell depolarization (due to closure of K ATP channel).
  • Increase in the intracellular cAMP level also activates Protein Kinase (PK-A & PK-C), which raises the cystolic Ca 2+ concentration, by opening of L-type of Ca 2+ channel.
  • PK-A & PK-C Protein Kinase
  • GLP-1 and glucagon sequences alignment shown below represent the primary structural relationships:
  • GLP-1 peptides are rapidly metabolized by the proteolytic enzymes, such as dipeptidyl peptidase-IV (DPP-IV) into an inactive metabolite, thereby limiting the use of GLP-1 as a drug ( Deacon, C. F., Regulatory Peptides, 2005, 128, 117 ).
  • DPP-IV dipeptidyl peptidase-IV
  • nonpeptidyl and peptidyl glucagon receptor antagonist of diverse structures have been reported over recent years, but none of them are in active development or under clinical trials ( Kurukulasuriya, R., Expert Opinion Therapeutic Patents, 2005, 15, 1739 ; Lau, J., J. Med. Chem., 2007, 50, 113 ; Petersen, K. F.
  • HTS has apparently yielded few hits ( US 2005/6927214 ; WO 2000/042026 ; US 2007/0043093 ), however, screening of those hits against corresponding receptors, especially under in vivo condition (animal models) prone to be false negatives ( Murphy, K.G., PNAS, 2007, 104, 689 ).
  • Glucagon and GLP-1 both play major roles in overall glucose homeostasis ( Drucker, D. J., J. Clin. Invest., 2007, 117, 24 ; Bollyky, J., J. Clin. Endocrinol. Metab., 2007, 92, 2879 ).
  • Glucagon increases plasma glucose concentrations by stimulating gluconeogenesis and glycogenolysis in the liver while GLP-1 lowers plasma glucose concentrations mediated by glucose dependent insulin secretion ( Mojsov, S., et al., JBC., 1990, 265, 8001 ).
  • Glucagon and GLP-1 have no defined structure in aqueous solution, but in the presence of micelles or in the membrane mimetic environment, they adopt an alpha-helical structure in the midsection, with flexible N- and C-terminal regions ( Thornton, K., Biochemistry, 1994, 33, 3532 ; Nommeh, J. W., Biochemistry, 2001, 40, 13188 ). This suggests that the helical structure is required for binding of peptide ligands to their respective receptors.
  • Xaa1-Xaa11 wherein Xaa1-Xaa9 represent the first 1-9 residues of GLP-1 peptide (HAEGTFTSD; Seq. ID No. 3), with some analogs wherein Xaa2 represents either Ala or are optionally replaced with Aib, Xaa3 represents amino acids with carboxylic acid side chain such as glutamic acid, aspartic acid etc. but not the Gln (Q), which is conserved in N-terminal sequence of Glucagon peptide (HSQGTFTSD, Seq. ID No. 4).
  • Xaa6 represents Phe or are optionally replaced with - ⁇ -Me-2F-Phe-
  • Xaa9 represent amino acids with carboxylic acid or amide side chains such as aspartic acid, glutamic acid, asparagine etc.
  • Xaa10 & Xaa11 represents combination of substituted or unsubstituted biphenyl alanine (Bip) derivatives ( WO 2003/ 033671A2 ; US 2004/ 0127423 A1 ; WO 2004/ 094461 A2 ; US 2006 / 0004222 A1 ; WO 2006/ 014287 A1 ; WO 2006/127948 A2 ; WO 2007/082264 A2 ; US 2007/0021346 A1 ; US2007/0099835 ).
  • the present invention provides novel peptidomimetics of formula (I) (hereinafter referred to as peptidomimetics), which primarily act as a glucagon receptor antagonist and also exhibit GLP-1R agonistic effects.
  • peptidomimetics which primarily act as a glucagon receptor antagonist and also exhibit GLP-1R agonistic effects.
  • Different peptidomimetics reported in this invention showed significant glucose dependent insulin secretion ( in vitro ) and reduce circulating glucose levels ( in vivo ) , with different level of affinity/selectivity towards glucagon and GLP-1 receptors.
  • these peptidomimetics showed increased stability to proteolytic cleavage, especially against DPP-IV enzyme with improved half-life.
  • peptidomimetics were found to be stable against GIT enzymes and acidic pH of stomach, with oral bioavailability, making them suitable candidate for the treatment / mitigation / prophylaxis of both type 1 & type 2 diabetes, metabolic disorders and related disorders.
  • glucagon and GLP-1 peptides raises the possibility of producing hybrid peptidomimetics that can bind with both the receptors, but selectively exhibit antagonistic activity at glucagon receptor and agonistic activity at GLP-1 receptor. Furthermore, in order to have oral bioavailibility and increased metabolic stability, it is also essential to develop peptidomimetics, with shorter amino acid sequence.
  • N-domain of GLP-1 and glucagon receptors determine the selectivity of the C-terminal portion of GLP-1 and glucagon peptides respectively ( Hoare, S.R.J., Drug. Discovery Today, 2005, 10, 423 ).
  • this concept indicates that incorporation of C-terminal sequence of GLP-1 (especially last 4 residues, VKGR) into glucagon sequence lead to the formation of novel peptides, which act as both GLP-1 receptor agonist and glucagon receptor antagonist.
  • binding component of GLP-1 peptide sequence is essential (atleast last 4 residues) and for activation of GLP-1 receptor and inhibition of glucagon receptor, N-terminal sequence of glucagon peptide is required.
  • N-terminal sequence of glucagon peptide is required.
  • DPP-IV enzyme which selectively cleave N-terminal dipeptide at the penultimate N-terminal position, it is essential to incorporate DPP-IV stable amino acid, especially at 2 nd position.
  • Oral route of drug administration is universally accepted by patients due to its ease of administration but it encounters absorption and enzymatic barriers along with the first-pass effect.
  • the oral route of drug administration is the route of choice, the delivery of peptide and protein drugs by this route is currently limited due to their poor permeability and rapid degradetion in the gastrointestinal tract. Therefore, most of the commercially available peptide and protein drugs are administered by the parenteral route. However, due to patient non-compliance and short half-life of peptide and protein drugs, the parenteral route of administration is not suitable for the delivery of these drugs.
  • Epithelia represent a good target for the delivery of biopharmaceuticals.
  • semi-permeable nature of epithelia limit the passage of peptide and protein drugs through their surfaces and thereby act as a principal absorption barrier ( Arhewon, I. M., African J. Biotechnology, 2005, 4, 1591 ).
  • the cell membrane of epithelial cells is made up of a continuous bilayer layer of membrane lipids and proteins.
  • the membrane lipids consist of amphiphilic phospholipids, such as phosphatidylcholine, sphingomyelin, phosphatidylserine and phosphatidylethanolamine, along with glycolipids and cholesterol molecules [ Figure 5 ] .
  • Phosphatidylcholine and sphingomyelin are neutral phospholipids, whereas phosphatidylserine are negatively charged phospholipid. At physiological pH, most epithelia exhibit net negative charge due to the presence of phosphatidylserine. Thus while designing our peptidomimetics, attempts were made to avoid net negative charge. In general, in all the sequences designed in this invention, net neutral charge was maintained, which could be possible by incorporation of first 1-9 residues of N-terminal sequence of glucagon peptide (Seq. ID No. 4) and not the first 1-9 residues of N-terminal sequence of GLP-1 peptide (Seq. ID No.
  • the present invention describes a group of novel peptidomimetics that function both as an antagonist of the glucagon receptor and agonist of the GLP-1 receptor, having different degree of affinity/selectivity towards both the receptors and useful for reducing circulating glucose levels and for the treatment of diabetes.
  • These peptidomimetics are defined by the general formula (I) as given below.
  • the peptidomimetics of the present invention are useful in the treatment of the human or animal body, by regulation of insulin and glucagon action.
  • the peptidomimetics of this invention are therefore suitable for the treatment/mitigation/regulation or prophylaxis of type 1 and type 2 diabetes and associated metabolic disorders.
  • a preferred embodiment of the present invention is to provide novel peptidomimetics of general formula (I), their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures, suitable for the treatment treatment/mitigation/regulation of diabetes.
  • novel peptidomimetics of the present invention as antidiabetic agents, by administering a therapeutically effective & non-toxic amount of the peptidomimetics of formula (I), or their pharmaceutically acceptable compositions to the mammals those are in need of such treatment.
  • synthetic peptidomimetics having the structural formula (I), which showed glucose dependent insulin secretion. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity. These dual acting peptidomimetics exhibit increased stability to proteolytic cleavage, especially against DPP-IV (Dipeptidyl peptidase-IV) enzyme. Most of peptidomimetics were found to be stable in rat plasma upto 24 hours ( in vitro ), showed increased stability against GIT enzymes such as pepsin and acidic stomach pH and also against liver microsomes (in vitro ).
  • DPP-IV Dipeptidyl peptidase-IV
  • A-Z 1 -Z 2 -Z 3 -Z 4 -Z 5 -Z 6 -Z 7 -Z 8 -Z 9 -Z 10 -Z 11 -B (I) wherein, A represents the groups NH-R 1 , R 3 -CO- or R 3 -SO 2 -, wherein R 1 represents hydrogen, or optionally substituted linear or branched (C 1 -C 10 ) alkyl chain; R 3 is selected from linear or branched (C 1 -C 10 ) alkyl, (C 3 -C 6 ) cycloalkyl, aryl, heteroaryl or arylalkyl groups.
  • the aryl group is selected from phenyl, napthyl, indanyl, fluorenyl or biphenyl, groups; the heteroaryl group is selected from pyridyl, thienyl, furyl, imidazolyl, benzofuranyl groups;
  • B represents -COOR 2 , -CONHR 2 or CH 2 OR 2 or a tetrazole, wherein R 2 represents H, optionally substituted groups selected from linear or branched (C 1 -C 10 ) alkyl group, aryl or aralkyl groups as defined earlier;
  • Z 1 represents Histidine (H);
  • Z 2 represents a naturally or unnaturally occurring amino acid selected from the group comprising of L-Serine, D-Serine, L-alanine, D-alanine, ⁇ -amino-isobutyric acid (Aib), 1-amino cyclopropane carboxylic acid (ACP);
  • Z 3 represents glutamine (Gl
  • Z 4 represents glycine (G) or the group 1-amino cyclopropane carboxylic acid (ACP);
  • Z 5 represents a naturally or nonnaturally occurring amino acid comprising a hydroxyl side chain; a preferred Z 5 is threonine or compounds of formula III
  • Z 6 represents a naturally or unnaturally occurring amino acid having a disubstituted alpha carbon having two side chains, wherein each of them may independently be an optionally substituted alkyl or aryl or an aralkyl group wherein the substituents may be selected from one or more alkyl groups or one or more halo groups.
  • Preferred Z 6 represents phenylalanine (Phe; F), alpha-methyl-phenylalanine (- ⁇ -Me-Phe-), alpha-methyl-2-fluorophenylalanine (- ⁇ -Me-2F-Phe-) or alpha-methyl-2,6-diflurophenylalanine (- ⁇ -Me-2,6-F-Phe-) or 2-fluorophenylalanine (-2F-Phe-) as given below.
  • Z 7 and Z 8 each independently represents a naturally or non-naturally occurring amino acid comprising a hydroxyl side chain, preferred Z 7 & Z 8 is independently selected from threonine, serine, 1-amino cyclopropane carboxylic acid (ACP) or compound of formula III as defined earlier; Z 9 independently represent a naturally or nonnaturally occurring amino acid having an amino acid side chain comprising an acidic group. Preferred Z 9 is selected from aspartic acid or compounds of formula II as defined earlier.
  • Z 10 represents a naturally or unnaturally occurring amino acid of formula IV
  • Z 11 represents a naturally or unnaturally occurring amino acids of formula V (a-d)
  • natural amino acids indicates all those twenty amino acids, which are present in nature.
  • 'unnatural amino acids' or 'non-natural amino acids' represents either replacement of L-amino acids with corresponding D-amino acids such as replacement of L-Ala with D-Ala and the like or suitable modifications of the L or D amino acids, amino alkyl acids, either by
  • alkyl used herein, either alone or in combination with other radicals, denotes a linear or branched radical containing one to ten carbons, such as methyl, methyl, n -propyl , iso- propyl, n -butyl, sec -butyl, tert -butyl, amyl, t -amyl, n- pentyl, n- hexyl, iso -hexyl, heptyl, octyl, decyl and the like.
  • cycloalkyl used herein, either alone or in combination with other radicals, denotes a radical containing three to seven carbons, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • aryl or "aromatic” used herein, either alone or in combination with other radicals, denotes an aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused, such as phenyl, naphthyl, tetrahydronaphthyl, indane, biphenyl, and the like.
  • arylalkyl denotes an alkyl group, as defined above, attached to an aryl, such as benzyl, phenylethyl, naphthylmethyl, and the like.
  • aryloxy denotes an aryl radical, as defined above, attached to an alkoxy group, such as phenoxy, naphthyloxy and the like, which may be substituted.
  • aralkoxy denotes an arylalkyl moiety, as defined above, such as benzyloxy, phenethyloxy, naphthylmethyloxy, phenylpropyloxy, and the like, which may be substituted.
  • heteroaryl or “heteroaromatic” used herein, either alone or in combination with other radicals, denotes an aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused containing one or more hetero atoms selected from O, N or S, such as pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzothienyl, indolinyl, indolyl, azaindolyl, azaindolinyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidinyl, pyr
  • heteroaryl used herein, either alone or in combination with other radicals, denotes a heteroaryl group, as defined above, attached to a straight or branched saturated carbon chain containing 1 to 6 carbons, such as (2-furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyl-1-(2-pyrimidyl)ethyl and the like.
  • heteroaryloxy “heteroaralkoxy”
  • heterocycloxy denotes heteroaryl, heteroarylalkyl, groups respectively, as defined above, attached to an oxygen atom.
  • acyl used herein, either alone or in combination with other radicals, denotes a radical containing one to eight carbons such as formyl, acetyl, propanoyl, butanoyl, iso-butanoyl, pentanoyl, hexanoyl, heptanoyl, benzoyl and the like, which may be substituted.
  • carboxylic acid used herein, alone or in combination with other radicals, denotes a -COOH group, and includes derivatives of carboxylic acid such as esters and amides.
  • ester used herein, alone or in combination with other radicals, denotes -COO- group, and includes carboxylic acid derivatives, where the ester moieties are alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, and the like, which may be substituted.
  • 'amino acid' as employed herein alone or as part of another group includes, without limitation, an amino group and a carboxyl group linked to the same carbon, referred to as ' ⁇ ' carbon.
  • the absolute 'S' configuration at the ' ⁇ ' carbon is commonly referred to as the 'L' or natural configuration.
  • the 'R' configuration at the ' ⁇ ' carbon is commonly referred to as the 'D' amino acid.
  • both the ' ⁇ -substituents' is equal, such as hydrogen or methyl, the amino acids are Gly or Aib and are not chiral.
  • 'receptor antagonist refers to compounds that inhibit the activation of receptor and generation of secondary messenger such as cyclic AMP either by competitive or non-competitive binding.
  • 'Glucagon receptor antagonist' refers to compounds that inhibit activation of glucagon receptor.
  • 'GLP-1 receptor modulator or agonist' refers to a compound that acts at the GLP-1 receptor to alter its ability to regulate downstream signaling events, such as cAMP production and insulin release.
  • Example of receptor modulators includes agonist, partial agonist, inverse agonist and allosteric potentiators.
  • the synthetic isolated peptidomimetics described herein primarily act as a glucagon receptor antagonist. Furthermore, it was found that these peptidomimetics also act as GLP-1 receptor agonists. These synthetic peptidomimetics exhibit desirable in vitro glucagon receptor antagonist properties as well as GLP-1 receptor agonist activity in CHO cells transfected with human glucagon or GLP-1 receptor (H Glucagon R or HGLP-1R), in the range of 1- 100 nM concentration.
  • H GLP-1 R agonistic activity is assessed by estimation of amount of cAMP released, while glucagon antagonistic activity was assessed by measuring the amount of cAMP production inhibited by the test peptidomimetics, in presence of glucagon peptide.
  • Novel peptidomimetics exhibit desirable in vitro glucagon receptor antagonist activity in CHO cells transfected with human glucagon receptor, in the range of 1- 100-nM concentration.
  • test peptidomimetics prepared showed glucose dependent insulin release and reduces fasting hyperglycemia, without causing hypoglycemia, when tested in vivo, in different diabetic animal models, such as hyperglycemic C57 mice and db / db mice, thus making them ideal therapeutic candidates for the treatment and prevention of type 2 diabetes.
  • These new classes of peptidomimetics can be administered by oral or parenteral routes of administration.
  • the present invention provides peptidomimetics of formula (I) pharmaceutical compositions employing such peptidomimetics either alone or in combination and for methods of using such peptidomimetics.
  • the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a peptidomimetics of formula (I), alone or in combination(s), with a pharmaceutically acceptable carrier.
  • a method for treating or delaying the progression or onset of diabetes especially type 2 diabetes, including complications of diabetes, including retinopathy, neuropathy, nephropathy and delayed wound healing and related diseases such as insulin resistance (impaired glucose homeostasis), hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia including hypertriglyceridemia, syndrome X, atherosclerosis and hypertension, wherein a therapeutically effective amount of a peptidomimetics of formula (I) or their combination(s) are administered to a mammal, example, human, a patient in need of treatment.
  • complications of diabetes including retinopathy, neuropathy, nephropathy and delayed wound healing and related diseases such as insulin resistance (impaired glucose homeostasis), hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia including hypertriglyceridemia, syndrome X, atherosclerosis and hypertension
  • the peptidomimetics thereof described herein may be produced by chemical synthesis using suitable variations of various solid-phase techniques generally known such as those described in G. Barany & R. B. Merrifield, "The peptides: Analysis, synthesis, Biology”; Volume 2- “Special methods in peptide synthesis, Part A", pp. 3-284, E. Gross & J. Meienhofer, Eds., Academic Press, New York, 1980 ; and in J. M. Stewart and J. D. Young, "Solid-phase peptide synthesis” 2nd Ed., Pierce chemical Co., Rockford, Il, 1984 .
  • the preferred strategy for preparing the peptidomimetics of this invention is based on the use of Fmoc-based SPPS approach, wherein Fmoc (9-Fluorenyl-methylmethyloxycarbonyl) group is used for temporary protection of the ⁇ -amino group, in combination with the acid labile protecting groups, such as t-butyloxy carbonyl (Boc), tert-butyl (Bu t ), Trityl (Trt) groups ( Figure 6 ), for temporary protection of the amino acid side chains (see for example E. Atherton & R.C.
  • Fmoc (9-Fluorenyl-methylmethyloxycarbonyl) group is used for temporary protection of the ⁇ -amino group, in combination with the acid labile protecting groups, such as t-butyloxy carbonyl (Boc), tert-butyl (Bu t ), Trityl (Trt) groups ( Figure 6 ), for temporary protection of the amino acid side chains
  • the peptidomimetics can be synthesized in a stepwise manner on an insoluble polymer support (resin), starting form the C-terminus of the peptide.
  • the synthesis is initiated by appending the C-terminal amino acid of the peptide to the resin through formation of an amide, ester or ether linkage. This allows the eventual release of the resulting peptide as a C-terminal amide, carboxylic acid or alcohol, respectively.
  • the C-terminal amino acid and all other amino acids used in the synthesis are required to have their ⁇ -amino groups and side chain functionalities (if present) differentially protected (orthogonal protection), such that the ⁇ -amino protecting group may be selectively removed during the synthesis, using suitable base such as 20% piperidine solution, without any premature cleavage of peptide from resin or deprotection of side chain protecting groups, usually protected with the acid labile protecting groups.
  • the coupling of an amino acid is performed by activation of its carboxyl group as an active ester and reaction thereof with unblocked ⁇ -amino group of the N-terminal amino acid appended to the resin. After every coupling and deprotection, peptidyl-resin was washed with the excess of solvents, such as DMF, DCM and diethyl ether. The sequence of ⁇ -amino group deprotection and coupling is repeated until the desired peptide sequence is assembled ( Scheme 1 ). The peptide is then cleaved from the resin with concomitant deprotection of the side chain functionalities, using an appropriate cleavage mixture, usually in the presence of appropriate scavengers to limit side reactions. The resulting peptide is finally purified by reverse phase HPLC.
  • the synthesis of the peptidyl-resins required as precursors to the final peptides utilizes commercially available cross-linked polystyrene polymer resins (Novabiochem, San Diego, CA).
  • Preferred for use in this invention are Fmoc-PAL-PEG-PS resin, 4-(2', 4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetyl-p-methyl benzhydrylamine resin (Fmoc-Rink amide MBHA resin), 2-chloro-Trityl-chloride resin or p-benzyloxybenzyl alcohol resin (HMP resin) to which the C-terminal amino acid may or may not be already attached.
  • Fmoc-PAL-PEG-PS resin 4-(2', 4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetyl-p-methyl benzhydrylamine resin
  • the C-terminal amino acid is not attached, its attachment may be achieved by HOBt active ester of the Fmoc-protected amino acid formed by its reaction with DIPCDI.
  • HOBt active ester of the Fmoc-protected amino acid formed by its reaction with DIPCDI.
  • 2-Chloro-trityl resin coupling of first Fmoc-protected amino acid was achieved, using DIPEA.
  • N-terminal protection of peptidyl resin was selectively deprotected using a solution of 10-20 % piperidine solution. After every coupling and deprotection, excess of amino acids and coupling reagents were removed by washing with DMF, DCM and ether.
  • Coupling of the subsequent amino acids can be accomplished using HOBt or HOAT active esters produced from DIPCDI/ HOBt or DIPCDI/HOAT, respectively.
  • HOBt or HOAT active esters produced from DIPCDI/ HOBt or DIPCDI/HOAT, respectively.
  • complete coupling can be achieved using a combination of highly efficient coupling agents such as HBTU, PyBOP or TBTU, with additives such as DIPEA.
  • the synthesis of the peptidomimetics described herein can be carried out by using batchwise or continuous flow peptide synthesis apparatus, such as CS-Bio or AAPPTEC peptide synthesizer, utilizing the Fmoc/t-butyl protection strategy.
  • the non-natural non-commercial amino acids present at different position were incorporated into the peptide chain, using one or more methods known in the art.
  • a Fmoc-protected non-natural amino acid was prepared in solution, using appropriate literature procedures.
  • the Fmoc-protected Bip analogs, described above were prepared using modified Suzuki cross coupling method, as known in literature ( Kotha, S., et al., Tetrahedron 2002, 58, 9633 ).
  • the Fmoc-protected ⁇ -methylated amino acids were prepared using asymmetric Strecker synthesis ( Boesten, W.H.J., et al., Org. Lett., 2001, 3(8), 1121 ). The resulting derivative was then used in the stepwise synthesis of the peptide. Alternatively, the required non-natural amino acid was built on the resin directly using synthetic organic chemistry procedures and a linear peptide chain were build.
  • the peptide-resin precursors for their respective peptidomimetics may be cleaved and deprotected using suitable variations of any of the standard cleavage procedures described in the literature ( King, D. S., et al., Int. J. Peptide Protein Res., 1990, 36, 255 ).
  • a preferred method for use in this invention is the use of TFA cleavage mixture, in the presence of water and TIPS as scavengers.
  • the peptidyl-resin was incubated in TFA / Water /TIPS (94:3:3; V: V: V; 10 ml / 100 mg of peptidyl resin) for 1.5-2 hrs at room temperature.
  • the cleaved resin is then filtered off, the TFA solution is concentrated or dried under reduced pressure.
  • the resulting crude peptide is either precipitated or washed with Et 2 O or is re-dissolved directly into DMF or 50 % aqueous acetic acid for purification by preparative HPLC.
  • Peptidomimetics with the desired purity can be obtained by purification using preparative HPLC.
  • the solution of crude peptide is injected into a semi-Prep column (Luna 10 ⁇ ; C 18 ; 100 A ° ), dimension 250 X 50 mm and eluted with a linear gradient of ACN in water, both buffered with 0.1 % TFA, using a flow rate of 15 -50 ml /min with effluent monitoring by PDA detector at 220 nm.
  • the structures of the purified peptidomimetics can be confirmed by Electrospray Mass Spectroscopy (ES-MS) analysis.
  • ES-MS Electrospray Mass Spectroscopy
  • peptide prepared were isolated as trifluoro-acetate salt, with TFA as a counter ion, after the Prep-HPLC purification.
  • some peptides were subjected for desalting, by passing through a suitable ion exchange resin bed, preferably through anion-exchange resin Dowex SBR P(Cl) or an equivalent basic anion-exchange resin.
  • TFA counter ions were replaced with acetate ions, by passing through suitable ion-exchange resin, eluted with dilute acetic acid solution.
  • selected peptides, with the acetate salt was treated with 4 M HCl.
  • the Fmoc-protection on first amino acid, coupled with resin was deprotected, using a 10-20% piperidine solution, followed by the coupling the Fmoc-protected second amino acid, using a suitable coupling agents, and as described above.
  • the repeated cycles of deprotection, washing, coupling and washing were performed until the desired peptide chain was assembled on resin, as per general Scheme 1 above.
  • the linear peptide chain, H 2 N-H-Aib-QGT-( ⁇ -Me-2F-Phe)-TSD-Bip(OMe)-Bip(2CF 3 )- PAL-PEG-PS was' assembled on an automated CS-Bio 536 PepSynthesiserTM using Fmoc solid phase peptide synthesis (SPPS) approach ( Scheme 2 ).
  • SPPS Fmoc solid phase peptide synthesis
  • the Fmoc amino acids and the 2-(1 H -Benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumtetrafluoroborate (TBTU) were packed together in vials and positioned in the amino acid module of the synthesizer.
  • a stock solution of diisopropylethylamine (DIPEA; 0.9 M) and DMF were stored in reagent bottles, under dry nitrogen atmosphere.
  • the resin, Fmoc-PAL-PEG-PS (0.38 mmol/g; 1g) was dried over P 2 O 5 , in vacuo (1 hr) and swollen in freshly distilled DMF (5 mL). The swollen resin was slurry packed into a glass column and positioned in the synthesizer. All the synthetic cycles were carried out at a flow rate of 5 mL min -1 Table 1 .
  • the resin was washed with freshly distilled DMF for 10 minutes.
  • Deprotection of Fmoc group was performed with 20% piperidine in DMF for 10 minutes and the deprotection was monitored by UV detection of the column effluent at 304 nm.
  • the aqueous layer was separated and freeze-dried to yield the crude peptide H 2 N-H-Aib-QGT-( ⁇ -Mc-2F-Phc)-TSD-Bip(OMe)-Bip(2CF 3 )-CONH 2 .
  • the lyophilised peptide H 2 N-H-Aib-QGT-( ⁇ -Me-2F-Phe)-TSD-Bip(OMe)-Bip(2CF 3 )-CONH 2 was dissolved in 0.1% aqueous TFA (ca 1mg /1 mL) and its purity was analyzed by analytical RP-HPLC and characterized by electrospray ionisation mass spectrometry (ESI-MS).
  • the desired peptidomimetics were cleaved and deprotected from their respective peptidyl-resins by treatment with TFA cleavage mixture as follows.
  • a solution of TFA / Water / Triisopropylsilane (95: 2.5: 2.5) (10 ml / 100 mg of peptidyl-resin) was added to peptidyl-resins and the mixture was kept at room temperature with occasional starring.
  • the resin was filtered, washed with a cleavage mixture and the combined filtrate was evaporated to dryness. Residue obtained was dissolved in 10 ml of water and the aqueous layer was extracted 3 times with ether (20 ml each) and finally the aqueous layer was freeze-dried.
  • Crude peptide obtained after freeze-drying was purified by preparative HPLC as follows:
  • Preparative HPLC was carried out on a Shimadzu LC-8A liquid chromatograph.
  • a solution of crude peptide dissolved in DMF or water was injected into a semi-Prep column (Luna 10 ⁇ ; C 18 ; 100 A 0 ), dimension 250 X 50 mm and eluted with a linear gradient of ACN in water, both buffered with 0.1 % TFA, using a flow rate of 15 -50 ml / min, with effluent monitoring by PDA detector at 220 nm.
  • a typical gradient of 20 % to 70 % of water-ACN mixture, buffered with 0.1 % TFA was used, over a period of 50 minutes, with 1% gradient change per minute.
  • the desired product eluted were collected in a single 10-20 ml fraction and pure peptidomimetics were obtained as amorphous white powders by lyophilisation of respective HPLC fractions.
  • each peptide was analyzed by analytical RP-HPLC on a Shimadzu LC-10AD analytical HPLC system.
  • analytical HPLC analysis of peptidomimetics Luna 5 ⁇ ; C 18 ; 100 A ° , dimension 250 X 4.6 mm column was used, with a linear gradient of 0.1% TFA and ACN buffer and the acquisition of chromatogram was carried out at 220 nm, using a PDA detector.
  • ESI-MS electrospray ionisation mass spectrometry
  • LC/MS mode electrospray ionisation mass spectrometry
  • Triple quadrupole mass spectrometers API-3000 (MDS-SCIES, Canada) was used in all analyses in positive and negative ion electrospray mode. Full scan data was acquired over the mass range of quadrupole, operated at unit resolution. In all cases, the experimentally measured molecular weight was within 0.5
  • novel peptidomimetics were prepared. This list is indicative of the various groups of peptidomimetics, which can be prepared according to the present invention, and are expected to at least include obvious variations of these peptidomimetics. However, such disclosure should not be construed as limiting the scope of the invention in any way.
  • Table 2-(i-vi) novel peptidomimetics of present invention are listed along with their corresponding Seq. ID. No. Table 2 (i): List of peptidomimetics prepared Seq. ID. No.
  • RIN5F Rat Insulinoma cells were cultured in RPMI 1640 medium supplemented with sodium pyruvate (1 mM) HEPES and Glucose (4.5 g/L) in a humidified incubator (5 % CO 2 ), at 37 °C. After trypsinization, RIN5F cells were seeded at a concentration of 0.2 X 10 6 cells per well, in 12 well plates. The cells were grown overnight to 80 % confluence and insulin secretion experiments were performed as follows (Montrose-Rafizadeh C., et al., Mol. Cell. Endo. 1997, 130, 109.; Wang, X., et al., Endocrinology 2001, 5, 1820).
  • the novel peptidomimetics were screened for Human GLP-1receptor (HGLP-1 R) agonist activity ( in vitro ), using the cAMP cell-based assay, in stably transfected CHO/ human GLP1R cells.
  • the CHO-K1 cells (CRL 9618) were. obtained from American Type Culture Collection (Rockville, MD). CHO cells were grown in Ham's F12 medium containing L-Glutamine (2mM), HEPES (25 mM), NaHCO 3 (1.1 g/L) and supplemented with NewBorn Calf Serum (NBCS; 10%), Penicillin (50 U /ml (v/v)) and Streptomycin (50 ug/ml (v/v)). Cells were split every 3 days 1:8.
  • the cDNA encoding the human GLP-1 receptor was isolated by RT- PCR according to standard protocol. The full-length cDNA was cloned in pcDNA3.1(+).
  • CHO cell lines expressing the GLP-1 receptor CHO cells were transfected with 10 ⁇ g of the expression plasmid pcDNA/hGLP-1R using CaPO 4 according to the standard protocol (Wheeler, M.B., et al., Endocrinology 1993, 133, 57.).
  • Clones expressing the receptor were generated by G418 (800 ⁇ g/ml active, Sigma) selection. The stable clones were thereafter maintained at 500 ug/ml (G418). The selected clone was used between passages 9-25 for cAMP assays.
  • the CHO cells stably transfected with human GLP-1R were maintained in Ham's F12 + 10% NBCS + 500 ug/ml G418 upto a confluency of 70-75%.
  • the cells were trypsinized using 2 ml of TPVG (0.25% trypsin, 0:53 mM EDTA, 1.38-mM glucose).
  • the trypsin was inactivated using Ham's F12 medium containing 10% NBCS and the cells were suspended in 2 ml of complete medium.
  • the medium was aspirated off and fresh medium (plain Ham's F12 + 1% BSA+ 0.25 mM RO-20) was added with 5ul of test compounds (peptidomimetics) that has been dissolved in water (MilliQ).
  • test compounds peptidomimetics
  • the cells were incubated with the test compounds for 30 min in humidified atmosphere and 37°C. After the incubation, the medium was removed and cells were washed once with plain Ham's F12. Subsequently, the cells were lysed by adding 500 ul of ice cold 0.1 N HCl to each well and shaking for 30 minutes at 200 rpm. The cells were then scrapped, the lysate was collected in micro centrifuge tubes and centrifuged at 12000 rpm for 10 min to remove the debris.
  • the novel peptidomimetics were screened for human glucagon receptor (H-glucagon-R) antagonistic activity ( in vitro ), using the cAMP cell-based assay, in stably transfected CHO/ human glucagon R cells.
  • the CHO-K1 cells (CRL 9618) were obtained from American Type Culture Collection (Rockville, MD). CHO cells were grown in Ham's F12 medium containing L-Glutamine (2mM), HEPES (25 mM), NaHCO 3 (1.1 g/L) and supplemented with newborn Calf Serum (NBCS; 10%), Penicillin (50 U /ml (v/v)) and Streptomycin (50 ug/ml (v/v)). Cells were split every 3 days 1:8.
  • the cDNA encoding the human glucagon receptor was isolated by RT- PCR according to standard protocol. The full-length cDNA was cloned in pcDNA3.1(Invitrogen).
  • CHO cells were transfected with 10 ⁇ g of the expression plasmid pcDNA/ H-glucagon-R using CaPO 4 according to the standard protocol.
  • Clones expressing the receptor were generated by G418 (800 ⁇ g/ml active, Sigma) selection. The stable clones were thereafter maintained at 500 ug/ml (G418). The selected clone was used between passages 9-25 for cAMP assays.
  • glucagon antagonistic activity by measuring amount of cAMP production inhibited after addition of test peptidomimetics along with glucagon peptide.
  • the CHO cells stably transfected with human glucagon R were maintained in Ham's F12 + 10% NBCS + 500 ug/ml G418 upto a confluency of 70-75%.
  • the cells were trypsinized using 2 ml of TPVG (0.25% trypsin, 0.53 mM EDTA, 1.38-mM glucose).
  • the trypsin was inactivated using Ham's F12 medium containing 10% NBCS and the cells were suspended in 2 ml of complete medium.
  • 2 X 10 5 cells /well were then seeded in 12 well plate and the plates were incubated in humidified atmosphere at 37°C for 16-18 h.The next day the assay was proceeded, when the cells showed 90-95% confluency.
  • the medium was aspirated off from the 12 well plate and the cells were washed once using Ham's F12 (plain). The cells were incubated at 37°C with 500 ul of Ham's F12 + 1% BSA+ 0.125 mM RO-20 for 30 min. After the incubation, the medium was aspirated off and fresh medium (plain Ham's F12 + 1% BSA+ 0.25 mM RO-20) was added with 5ul of test compounds (peptidomimetics) that has been dissolved in water (MilliQ), followed by addition of glucagon peptide (as agonist). The cells were incubated with the peptidomimetics and glucagon peptide for 30 min in humidified atmosphere and 37 °C.
  • test compounds peptidomimetics
  • glucagon peptide as as agonist
  • the medium was removed and cells were washed once with plain Ham's F12. Subsequently, the cells were lysed by adding 500 ul of ice cold 0.1 N HCl to each well and shaking for 30 minutes at 200 rpm. The cells were then scrapped, the lysate was collected in micro centrifuge tubes and centrifuged at 12000 rpm for 10 min to remove the debris. 300 ul of supernatant from each micro-centrifuge tube was then removed into a glass tube and dried under N 2 for 30 min, for cAMP estimation. The total cAMP was estimated from the sample according to the manufacturer's protocol using Cyclic AMP immunoassay kit (R&D systems, Minneapolis. MN).
  • Different peptidomimetics were incubated with either DPP IV (1: 25 mU) or pooled human plasma (7.5 ⁇ L) or simulated gastric fluid (pH 1.5; composition HCl, NaCl and Pepsin) or simulated intestinal fluid (pH 7.5) or human liver microsomes, for 0, 2, 4, 6, 12 and 24 h (37 °C; 50 mM triethanolamine-HCl buffer; pH 7.8).
  • DPP IV enzyme/ human plasma/ simulated gastric fluid/ simulated intestinal fluid/ human liver microsomes were selected in preliminary experiments to provide degradation of approximately 50% of Exendin within 2-4 h, therefore allowing time-dependent degradation to be viewed over 24 h.
  • reaction products were terminated by the addition of TFA/H 2 O (15 mL, 10% (v/v)).
  • the reaction products were then applied to a Vydac C 18 analytical column (4.6 x 250-mm) and the major degradation fragment separated from intact peptidomimetic.
  • the column was equilibrated with TFA/H 2 0, at a flow rate of 1 mL/min.
  • TFA/H 2 0.1% (v/v) TFA in 70% acetonitrile/H 2 O
  • concentration of acetonitrile in the eluting solvent was raised from 0% to 28% over 10 min and from 28% to 42% over 30 min.
  • the absorbance was monitored at 206 nm using UV detector and peaks were collected manually prior to ESI-MS analysis.
  • Stability study results of selected peptidomimetics, against DPP IV enzyme, human plasma, simulated gastric fluid, intestinal fluid and liver microsomes ( in vitro ) are listed in Table 6 .
  • Table 6 Stability study results of selected peptidomimetics against DPP IV enzyme, human plasma, simulated gastric fluid, intestinal fluid and liver microsomes ( in vitro ) Seq. ID. No.
  • DPP IV enzyme a Human plasma b Simulated gastric fluid c Simulated intestinal fluid d liver microsomes e EX-4 89 (6) 86 (6.2) 100 (0.3) 100 (0.3) 100 (0.4) 5 76(10) 78(9) 100 (0.5) 100 (0.5) 100 (0.5) 100 (0.5) 6 75(10) 77(9) 100 (0.5) 100 (0.5) 100 (0.5) 100 (0.5) 7 77(10) 80(9) 100 (0.5) 100 (0.5) 100 (0.5) 100 (0.5) 8 76(10) 78(9) 100 (0.5) 100 (0.5) 100 (0.5) 9 74(10) 75(9) 100 (0.5) 100 (0.5) 100 (0.5) 10 70(10) 71(9) 100 (0.5) 100 (0.5) 11 86(10) 70(9) 100 (0.5) 100 (0.5) 100 (0.5) 12 72(10) 70(9) 100 (0.5) 100 (0.5) 100 (0.5) 13 00 (>24) 00 (>24) 50 (4) 00 (>24) 86 (2) 14 00 (>
  • Acute single dose 120-min time-course experiments were carried out in male C57BL/6J or db/db mice, age 8-12 weeks, bred in-house. Animals were housed in groups of 6 animals per cage, for a week, in order to habituate them to vivarium conditions (25 ⁇ 4 °C, 60-65 % relative humidity, 12: 12 h light: dark cycle, with lights on at 7.30 am). All the animal experiments were carried out according to the internationally valid guidelines following approval by the 'Zydus Research Center animal ethical committee'.
  • Treatment group 0 min 30 min 60 min 120 min C57 control 183 ⁇ 6.2 186 ⁇ 6.1 188 ⁇ 5.2 181 ⁇ 5.4
  • in vitro antagonistic activity of peptidomemtics were estimated by measuring the inhibition of amount of cAMP production, with test peptidomemtics, when incubated along with the glucagon peptide.
  • Table 5 in general, all the peptidomimetics showed significant glucagon receptor antagonistic activity, in the range of 1nM to 1000 nM.
  • the novel peptidomimetics showed concentration dependent cAMP production ( in vitro GLP-1 agonist activity), in the range of 1-100 nM concentration ( Table 4 ).
  • novel peptidomimetics exhibit glucagon antagonistic and GLP-1 agonistic activity and are orally bioavailable, which make them ideal candidate for the safe and effective treatment of type 2 diabetes and associated metabolic disorders.
  • the present invention provides a method of making a peptidomimetic, that function both as an antagonist of the glucagon receptor and agonist of the GLP-1 receptor having different degree of affinity/selectivity towards both the receptors and useful for reducing circulating glucose levels & for the treatment of diabetes.
  • the synthetic peptidomimetic described in the present embodiment exhibit desirable in vitro Glucagon antagonistic and GLP-1 agonist activity in CHO cells transfected with human glucagon or HGLP-1R, in nM concentration, and in vivo, some of the peptidomimetics showed glucose dependent insulin release and reduces fasting hyperglycemia, without causing hypoglycemia, when tested in different diabetic animal models, such as hyperglycemic C57 mice and db / db mice.
  • Novel peptidomemtics of present invention showed increased stability against various proteolytic enzymes and due to increased stability and short chain length, such peptidomimetics can also be delivered by oral route of administration, along with other invensive and non-invensive routes of administration.
  • novel peptidomimetics of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients as are well known.
  • composition is provided by employing conventional techniques.
  • composition is in unit dosage form containing an effective amount of the active component, that is, the peptidomimetics of formula (I) either alone or combination, according to this invention.
  • the quantity of active component that is, the peptidomimetics of formula (I) according to this invention, in the pharmaceutical compositions and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular peptidomimetics and the desired concentration. Generally, the quantity of active component will range between 0.5 % to 90 % by weight of the composition.
  • the peptidomimetics of the present invention can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders, including, but not limited to, treating or delaying the progression or onset of diabetes (preferably type II, impaired glucose tolerance, insulin resistance and diabetic complications, such as nephropathy, retinopathy, neuropathy and cataracts), hyperglycemia, hyperinsulinemia, hypercholesterolemia, elevated blood levels of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, wound healing, tissue ischemia, atherosclerosis, hypertension, intestinal diseases (such as necrotizing enteritis, microvillus inclusion disease or celic disease).
  • the peptidomimetics of the present invention may also be utilized to increase the blood levels of high-density lipoprotein (HDL).
  • HDL high-density lipoprotein
  • peptidomimetics of the present invention may optionally be used in combination with suitable DPP-IV inhibitors for the treatment of some of the above disease states either by administering the compounds sequentially or as a formulation containing the peptidomimetics of the present invention along with a suitable DPP-IV inhibitors.
  • peptidomimetics of invention No adverse effects were observed for any of the mentioned peptidomimetics of invention.
  • the compounds of the present invention showed good glucose serum-lowering activity in the experimental animals used.
  • These peptidomimetics are used for the testing/ prophylaxis of diseases caused by hyperinsulinemia, hyperglycemia such as NIDDM, metabolic disorders, since such diseases are inter-linked to each other.

Claims (15)

  1. Peptidomimétique isolé, présentant une séquence de formule (I), y compris ses formes tautomères et ses solvats :

            A-Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-Z11-B     (I)

    dans laquelle
    - A représente un groupe symbolisé par -NH-R1, R3-CO- ou R3-SO2-, où R1 représente un atome d'hydrogène ou un groupe alkyle en C1-C10 à chaîne linéaire ou ramifiée, en option porteur de substituant(s), et R3 représente un groupe choisi parmi les groupes alkyle en C1-C10 à chaîne linéaire ou ramifiée, cycloalkyle en C3-C6, aryle, hétéroaryle ou aryl-alkyle,
    - B représente un groupe tétrazolyle ou un groupe symbolisé par -COOR2, -CONHR2 ou -CH2OR2 où R2 représente un atome d'hydrogène ou un groupe choisi parmi les groupes alkyle en C1-C10 à chaîne linéaire ou ramifiée, aryle ou aryl-alkyle, en option porteurs de substituant(s),
    - Z1 représente un résidu d'histidine,
    - Z2 représente un résidu d'un acide aminé naturel ou non-naturel, choisi dans l'ensemble formé par les L-sérine, D-sérine, L-alanine, D-alanine, acide α-amino-isobutyrique et acide 1-amino-cyclopropane-carboxylique,
    - Z3 représente un résidu de glutamine (symbolisé par Gln ou Q) ou du composé de formule II :
    Figure imgb0233
     soit l'acide 2-amino-4-cyano-butyrique (symbolisé par CNB),
    - Z4 représente un résidu de glycine ou d'acide 1-amino-cyclopropane-carboxylique,
    - Z5 représente un résidu d'un acide aminé naturel ou non-naturel, doté d'une chaîne latérale portant un groupe hydroxyle,
    - Z6 représente un résidu d'un acide aminé naturel ou non-naturel, dont l'atome de carbone en a porte deux substituants qui sont deux chaînes latérales choisies, chacune indépendamment, parmi les groupes alkyle, aryle et aralkyle, en option porteurs d'un ou de substituant(s) qui est ou sont choisi(s) parmi un ou plusieurs groupe(s) alkyle et un ou plusieurs atome(s) d'halogène,
    - Z7 et Z8 représentent chacun, indépendamment, un résidu d'un acide aminé naturel ou non-naturel, doté d'une chaîne latérale portant un groupe hydroxyle,
    - Z9 représente, indépendamment, un résidu d'un acide aminé naturel ou non-naturel, doté d'une chaîne latérale d'acide aminé comportant un groupe acide,
    - Z10 représente un résidu d'un acide aminé naturel ou non-naturel, de formule IV :
    Figure imgb0234
     symbolisé par Bip(OMe),
    - et Z11 représente un résidu d'un acide aminé naturel ou non-naturel, de l'une des formules (V-a) à (V-d) :
    Figure imgb0235
    Figure imgb0236
  2. Composé de formule I, conforme à la revendication 1, dans lequel Z5 représente un résidu de thréonine.
  3. Composé de formule I, conforme à la revendication 1, dans lequel Z5 représente un résidu d'un composé de formule III :
    Figure imgb0237
     où l'indice n vaut 0 ou 1, soit un acide de type 4-hydroxy-pyrrolidine-2-carboxylique (symbolisé par PCA).
  4. Composé de formule I, conforme à la revendication 1, dans lequel Z6 représente un résidu de phényl-alanine (Phe ou F), d'alpha-méthyl-phényl-alanine (αMe-Phe), d'alpha-méthyl-2-fluoro-phényl-alanine (αMe-2F-Phe), d'alpha-méthyl-2,6-difluorophényl-alanine (αMe-2,6F-Phe) ou de 2-fluoro-phényl-alanine (2F-Phe).
  5. Composé de formule I, conforme à la revendication 1, dans lequel chacun des symboles Z7 et Z8 représente un résidu choisi indépendamment parmi ceux de thréonine, de sérine, d'acide 1-amino-cyclopropane-carboxylique ou d'un composé de formule III :
    Figure imgb0238
     où l'indice n vaut 0 ou 1, soit un acide de type 4-hydroxy-pyrrolidine-2-carboxylique (symbolisé par PCA).
  6. Composé de formule I, conforme à la revendication 1, dans lequel Z9 représente un résidu choisi parmi ceux d'acide aspartique et du composé de formule II :
    Figure imgb0239
     soit l'acide 2-amino-4-cyano-butyrique (symbolisé par CNB).
  7. Composé de formule I :

            A-Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-Z11-B     (I)

    dans laquelle
    - A représente un groupe symbolisé par -NH-R1, R3-CO- ou R3-SO2-, où R1 représente un atome d'hydrogène ou un groupe alkyle en C1-C10 à chaîne linéaire ou ramifiée, en option porteur de substituant(s), et R3 représente un groupe choisi parmi les groupes alkyle en C1-C10 à chaîne linéaire ou ramifiée, cycloalkyle en C3-C6, aryle, hétéroaryle ou aryl-alkyle,
    - B représente un groupe tétrazolyle ou un groupe symbolisé par -COOR2, -CONHR2 ou -CH2OR2 où R2 représente un atome d'hydrogène ou un groupe choisi parmi les groupes alkyle en C1-C10 à chaîne linéaire ou ramifiée, aryle ou aryl-alkyle, en option porteurs de substituant(s),
    - Z1 représente un résidu d'histidine (symbolisé par H),
    - Z2 représente un résidu choisi parmi ceux des L-sérine, D-sérine, L-alanine, D-alanine, acide α-amino-isobutyrique et acide 1-amino-cyclopropane-carboxylique,
    - Z3 représente un résidu de glutamine (symbolisé par Gln ou Q) ou du composé de formule II :
    Figure imgb0240
     soit l'acide 2-amino-4-cyano-butyrique (symbolisé par CNB),
    - Z4 représente un résidu de glycine ou d'acide 1-amino-cyclopropane-carboxylique,
    - Z5 représente un résidu choisi parmi ceux de thréonine et d'un composé de formule III :
    Figure imgb0241
     où l'indice n vaut 0 ou 1, soit un acide de type 4-hydroxy-pyrroli-dine-2-carboxylique (symbolisé par PCA).
    - Z6 représente un résidu choisi parmi ceux de phényl-alanine (Phe ou F), d'alpha-méthyl-phényl-alanine (αMe-Phe), d'alpha-méthyl-2-fluoro-phényl-alanine (αMe-2F-Phe), d'alpha-méthyl-2,6-difluoro-phényl-alanine (αMe-2,6F-Phe) ou de 2-fluoro-phényl-alanine (2F-Phe),
    - Z7 et Z8 représentent chacun un résidu choisi indépendamment parmi ceux de thréonine, de sérine, d'acide 1-amino-cyclopropane-carboxylique ou d'un composé de formule III défini ci-dessus,
    - Z9 représente, indépendamment, un résidu d'acide aspartique ou du composé de formule II défini ci-dessus,
    - Z10 représente un résidu d'un acide aminé naturel ou non-naturel, de formule IV :
    Figure imgb0242
     symbolisé par Bip(OMe),
    - et Z11 représente un résidu d'un acide aminé naturel ou non-naturel, de l'une des formules (V-a) à (V-d) :
    Figure imgb0243
    Figure imgb0244
  8. Composé de formule I, conforme à la revendication 1, pour lequel les groupes aryle sont choisis parmi les groupes phényle, naph-tyle, indanyle, fluorényle et biphényle.
  9. Composé de formule I, conforme à la revendication 1, pour lequel le groupe hétéroaryle est choisi parmi les groupes pyridyle, thiényle, furyle, imidazolyle et benzofuranyle.
  10. Composé de formule I, choisi parmi les suivants :
    HSQGTFTSD-Bip(OMe)-Bip(2Me)
    HSQGTFTSD-Bip(OMe)-Bip(Pyr)
    HSQGTFTSD-Bip(OMe)-Bip(2F)
    HSQGTFTSD-Bip(OMe)-Bip(2CF3)
    HAQGTFTSD-Bip(OMe)-Bip(2Me)
    HAQGTFTSD-Bip(OMe)-Bip(Pyr)
    HAQGTFTSD-Bip(OMe)-Bip(2F)
    HAQGTFTSD-Bip(OMe)-Bip(2CF3)
    H-Aib-QGTFTSD-Bip(OMe)-Bip(2Me)
    H-Aib-QGTFTSD-Bip(OMe)-Bip(Pyr)
    H-Aib-QGTFTSD-Bip(OMe)-Bip(2F)
    H-Aib-QGTFTSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-QGTFTSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-QGTFTSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-QGTFTSD-Bip(OMe)-Bip(2F)
    H-(ACP)-QGTFTSD-Bip(OMe)-Bip(2CF3)
    HSQGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HSQGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HSQGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HSQGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HAQGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HAQGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HAQGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HAQGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-Aib-QGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-Aib-QGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-Aib-QGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-Aib-QGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-QGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-QGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-QGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-(ACP)-QGT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HSQGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HSQGT-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HSQGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HSQGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HAQGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HAQGT-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HAQGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HAQGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-Aib-QGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-Aib-QGT-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-Aib-QGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-Aib-QGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-QGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-QGT-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-QGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-(ACP)-QGT-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HS-(CNB)-GTFTSD-Bip(OMe)-Bip(2Me)
    HS-(CNB)-GTFTSD-Bip(OMe)-Bip(Pyr)
    HS-(CNB)-GTFTSD-Bip(OMe)-Bip(2F)
    HS-(CNB)-GTFTSD-Bip(OMe)-Bip(2CF3)
    HA-(CNB)-GTFTSD-Bip(OMe)-Bip(2Me)
    HA-(CNB)-GTFTSD-Bip(OMe)-Bip(Pyr)
    HA-(CNB)-GTFTSD-Bip(OMe)-Bip(2F)
    HA-(CNB)-GTFTSD-Bip(OMe)-Bip(2CF3)
    H-Aib-(CNB)-GTFTSD-Bip(OMe)-Bip(2Me)
    H-Aib-(CNB)-GTFTSD-Bip(OMe)-Bip(Pyr)
    H-Aib-(CNB)-GTFTSD-Bip(OMe)-Bip(2F)
    H-Aib-(CNB)-GTFTSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-(CNB)-GTFTSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-(CNB)-GTFTSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-(CNB)-GTFTSD-Bip(OMe)-Bip(2F)
    H-(ACP)-(CNB)-GTFTSD-Bip(OMe)-Bip(2CF3)
    HS-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HS-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HS-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HS-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HA-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HA-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HA-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HA-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-Aib-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-Aib-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-Aib-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-Aib-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-(ACP)-(CNB)-GT-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HS-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HS-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HS-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HS-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HA-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HA-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HA-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HA-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-Aib-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-Aib-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-Aib-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-Aib-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-(ACP)-(CNB)-GT-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HSQ-(ACP)-TFTSD-Bip(OMe)-Bip(2Me)
    HSQ-(ACP)-TFTSD-Bip(OMe)-Bip(Pyr)
    HSQ-(ACP)-TFTSD-Bip(OMe)-Bip(2F)
    HSQ-(ACP)-TFTSD-Bip(OMe)-Bip(2CF3)
    HAQ-(ACP)-TFTSD-Bip(OMe)-Bip(2Me)
    HAQ-(ACP)-TFTSD-Bip(OMe)-Bip(Pyr)
    HAQ-(ACP)-TFTSD-Bip(OMe)-Bip(2F)
    HAQ-(ACP)-TFTSD-Bip(OMe)-Bip(2CF3)
    H-Aib-Q-(ACP)-TFTSD-Bip(OMe)-Bip(2Me)
    H-Aib-Q-(ACP)-TFTSD-Bip(OMe)-Bip(Pyr)
    H-Aib-Q-(ACP)-TFTSD-Bip(OMe)-Bip(2F)
    H-Aib-Q-(ACP)-TFTSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-Q-(ACP)-TFTSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-Q-(ACP)-TFTSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-Q-(ACP)-TFTSD-Bip(OMe)-Bip(2F)
    H-(ACP)-Q-(ACP)-TFTSD-Bip(OMe)-Bip(2CF3)
    HSQ-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HSQ-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HSQ-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HSQ-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HAQ-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HAQ-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HAQ-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HAQ-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-Aib-Q-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-Aib-Q-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-Aib-Q-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-Aib-Q-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-Q-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-Q-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-Q-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-(ACP)-Q-(ACP)-T-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HSQ-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HSQ-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HSQ-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HSQ-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HAQ-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HAQ-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HAQ-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HAQ-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-Aib-Q-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-Aib-Q-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-Aib-Q-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-Aib-Q-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-Q-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-Q-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-Q-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-(ACP)-Q-(ACP)-T-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HSQG-(PCA)-FTSD-Bip(OMe)-Bip(2Me)
    HSQG-(PCA)-FTSD-Bip(OMe)-Bip(Pyr)
    HSQG-(PCA)-FTSD-Bip(OMe)-Bip(2F)
    HSQG-(PCA)-FTSD-Bip(OMe)-Bip(2CF3)
    HAQG-(PCA)-FTSD-Bip(OMe)-Bip(2Me)
    HAQG-(PCA)-FTSD-Bip(OMe)-Bip(Pyr)
    HAQG-(PCA)-FTSD-Bip(OMe)-Bip(2F)
    HAQG-(PCA)-FTSD-Bip(OMe)-Bip(2CF3)
    H-Aib-QG-(PCA)-FTSD-Bip(OMe)-Bip(2Me)
    H-Aib-QG-(PCA)-FTSD-Bip(OMe)-Bip(Pyr)
    H-Aib-QG-(PCA)-FTSD-Bip(OMe)-Bip(2F)
    H-Aib-QG-(PCA)-FTSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-QG-(PCA)-FTSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-QG-(PCA)-FTSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-QG-(PCA)-FTSD-Bip(OMe)-Bip(2F)
    H-(ACP)-QG-(PCA)-FTSD-Bip(OMe)-Bip(2CF3)
    HSQG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HSQG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HSQG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HSQG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HAQG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HAQG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HAQG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HAQG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-Aib-QG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-Aib-QG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-Aib-QG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-Aib-QG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-QG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-QG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-QG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-(ACP)-QG-(PCA)-(αMe-2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HSQG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HSQG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HSQG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HSQG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    HAQG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    HAQG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    HAQG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    HAQG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-Aib-QG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-Aib-QG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-Aib-QG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-Aib-QG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3)
    H-(ACP)-QG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2Me)
    H-(ACP)-QG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(Pyr)
    H-(ACP)-QG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2F)
    H-(ACP)-QG-(PCA)-(2F-Phe)-TSD-Bip(OMe)-Bip(2CF3).
  11. Composition pharmaceutique comprenant un composé de formule (I), conforme à l'une des revendications précédentes, et un ou des véhicule(s) approprié(s), pharmacologiquement admissible(s).
  12. Composés de formule (I), conforme à la revendication 1, ou compositions pharmaceutiques qui en contiennent, qui exercent une action d'antagoniste du récepteur de glucagon.
  13. Composés de formule (I), conforme à la revendication 1, ou compositions pharmaceutiques qui en contiennent, qui exercent en outre une action d'agoniste du récepteur du peptide GLP-1.
  14. Composé de formule (I), conforme à l'une des revendications 1 à 10, ou composition pharmaceutique conforme à la revendication 11, pour utilisation dans le traitement ou la prévention de maladies provoquées par une hyperlipidémie, une hypercholestérolémie, une hyperglycémie, une hyperinsulinémie, des taux sanguins élevés d'acides gras libres ou de glycérol, une hypertriglycéridémie, une cicatrisation, une intolérance au glucose, une résistance à la leptine, une résistance à l'insuline ou d'autres complications diabétiques.
  15. Composé conforme à la revendication 14, pour utilisation dans le traitement ou la prévention d'un diabète de type 2, d'une intolérance au glucose, d'une dyslipidémie, d'une hypertension, d'une athérosclérose, d'une hyperlipidémie, d'une insuffisance coronarienne, de troubles cardiovasculaires ou d'autres maladies dans lesquelles une résistance à l'insuline constitue le mécanisme pathophysiologique sous-jacent.
EP07866718.5A 2006-10-03 2007-09-28 Composés antidiabétiques Active EP2084182B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1632MU2006 2006-10-03
IN1965MU2006 2006-11-30
IN423MU2007 2007-03-06
PCT/IN2007/000457 WO2008062457A2 (fr) 2006-10-03 2007-09-28 Composés antidiabétiques

Publications (2)

Publication Number Publication Date
EP2084182A2 EP2084182A2 (fr) 2009-08-05
EP2084182B1 true EP2084182B1 (fr) 2013-08-28

Family

ID=39430173

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07866718.5A Active EP2084182B1 (fr) 2006-10-03 2007-09-28 Composés antidiabétiques

Country Status (9)

Country Link
US (1) US8841413B2 (fr)
EP (1) EP2084182B1 (fr)
JP (1) JP5247708B2 (fr)
AU (1) AU2007323035B2 (fr)
CA (1) CA2665033C (fr)
DK (1) DK2084182T3 (fr)
MX (1) MX2009003400A (fr)
NZ (1) NZ576023A (fr)
WO (1) WO2008062457A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020098657A1 (fr) * 2018-11-12 2020-05-22 天津药物研究院有限公司 Peptide dérivé du glucagon ayant une action agoniste de récepteur double et son utilisation

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2707448C (fr) * 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetiques antagoniste de glucagon et agoniste de glp-1
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
JP5840498B2 (ja) * 2008-12-05 2016-01-06 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ プロテアーゼ耐性ポリペプチドを選択するための方法
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
EP2491054A2 (fr) 2009-10-22 2012-08-29 Cadila Healthcare Limited Antagoniste des récepteurs du glucagon et agoniste du glp-i actifs par voie orale, à base de peptidomimétiques à chaîne courte
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2658859A4 (fr) 2010-12-30 2014-07-30 Enanta Pharm Inc Inhibiteurs macrocycliques de sérine protéase d'hépatite c
BR112013016480A2 (pt) 2010-12-30 2016-09-20 Abbvie Inc macrocíclo da fenantridina inibadores da protease da serina da hepatite c
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
EP3273981B1 (fr) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Procédé et composition pharmaceutique pour une utilisation dans le traitement du diabète
KR102414503B1 (ko) 2016-03-17 2022-06-29 티오제네시스 테라퓨틱스, 인크. 시스테아민의 조절 방출을 위한 조성물 및 시스테아민 민감성 장애의 전신 치료
CA3019594A1 (fr) * 2016-04-01 2017-10-05 University Of Washington Polypeptides capables de former des homo-oligomeres ayant une specificite mediee par des reseaux de liaisons hydrogene modulaires et leur conception
WO2019060634A1 (fr) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. Méthodes de traitement des troubles sensibles à la cystéamine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005664A1 (en) * 2000-04-25 2004-01-08 Millennium Pharmaceuticals, Inc. Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 molecules and uses therefor
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
NZ531788A (en) * 2001-10-18 2008-01-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
EA200702419A1 (ru) * 2005-05-05 2008-04-28 Кадила Хелзкэр Лимитед Новые соединения как агонисты glp-1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020098657A1 (fr) * 2018-11-12 2020-05-22 天津药物研究院有限公司 Peptide dérivé du glucagon ayant une action agoniste de récepteur double et son utilisation

Also Published As

Publication number Publication date
DK2084182T3 (da) 2013-11-04
EP2084182A2 (fr) 2009-08-05
JP5247708B2 (ja) 2013-07-24
US20130225488A1 (en) 2013-08-29
AU2007323035A1 (en) 2008-05-29
AU2007323035B2 (en) 2011-11-24
US8841413B2 (en) 2014-09-23
WO2008062457A3 (fr) 2008-10-02
CA2665033C (fr) 2013-10-01
CA2665033A1 (fr) 2008-05-29
MX2009003400A (es) 2009-04-28
WO2008062457A2 (fr) 2008-05-29
JP2010505820A (ja) 2010-02-25
WO2008062457A8 (fr) 2008-08-07
NZ576023A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
EP2084182B1 (fr) Composés antidiabétiques
US8883963B2 (en) Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities
US9884093B2 (en) Glucagon receptor agonists
WO2014049610A2 (fr) Peptides en tant que triples agonistes des récepteurs de gip, glp-1 et glucagon
EP2718317B1 (fr) Analogues de polypeptides insulinotropes dépendants du glucose, compositions pharmaceutiques et son utilisation
JP2017512800A (ja) エキセンジン−４に由来するペプチド二重ｇｌｐ−１／グルカゴン受容体アゴニスト
JP2017517483A (ja) エキセンジン−４に由来する二重ｇｌｐ−１／グルカゴン受容体アゴニスト
CN110845601B (zh) 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
EP1891106A2 (fr) Nouveaux composes utilises en tant qu'agonistes de glp-i
US20230102339A1 (en) Incretin analogs and uses thereof
US20120264685A1 (en) Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
CN101223189A (zh) 作为glp-i激动剂的新颖化合物
WO2024059674A1 (fr) Composés agonistes doubles de gip et de glp-1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090423

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20120515

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: R. A. EGLI AND CO. PATENTANWAELTE, CH

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 629306

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007032588

Country of ref document: DE

Effective date: 20131024

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 629306

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130828

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131230

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130731

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131129

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007032588

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140530

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007032588

Country of ref document: DE

Effective date: 20140530

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20140918

Year of fee payment: 8

Ref country code: CH

Payment date: 20140919

Year of fee payment: 8

Ref country code: DE

Payment date: 20140922

Year of fee payment: 8

Ref country code: DK

Payment date: 20140919

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20140919

Year of fee payment: 8

Ref country code: SE

Payment date: 20140918

Year of fee payment: 8

Ref country code: GB

Payment date: 20140919

Year of fee payment: 8

Ref country code: LU

Payment date: 20141001

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20140918

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130828

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070928

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007032588

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20150930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150928

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150929

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20151001

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20160531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150930

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160401

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150928

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150930

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151001

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150930